November 6, 2018
Hepatocellular carcinoma recurrence rates and patterns did not differ between patients who underwent interferon-based antiviral therapy for hepatitis C and those who received direct-acting antiviral therapy, according to a recently published study.
“With the development of direct-acting antivirals (DAA), patients with a history of HCC can achieve a high sustained viral response (SVR) rate with favorable tolerability,” Mizuki N. Kinoshita, MD, from the University of Tokyo, and colleagues wrote. “However, a high rate of early tumor recurrence has been reported in patients with a prior history of HCC treatment who were starting DAA treatment, for which we have presented counterevidence.”
Read More: https://www.healio.com/hepatology/hepatitis-c/news/online/%7Be554943e-f94f-4688-8069-fe88a24f854b%7D/hcc-recurrence-rates-do-not-differ-after-interferon-vs-daa-therapy
On This Blog
Liver Cancer After Treatment For Hepatitis CRead More: https://www.healio.com/hepatology/hepatitis-c/news/online/%7Be554943e-f94f-4688-8069-fe88a24f854b%7D/hcc-recurrence-rates-do-not-differ-after-interferon-vs-daa-therapy
On This Blog
This page offers an index of research articles investigating the possible risk of developing liver cancer (hepatocellular carcinoma, or HCC) during or after direct-acting antiviral therapy in patients with hepatitis C.
No comments:
Post a Comment